Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Colorectal Neoplasms 10Breast Neoplasms 9Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Adenomatous Polyposis Coli 4Sarcoma 3Glioblastoma 3Central Nervous System Neoplasms 3Paranasal Sinus Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Laryngeal Neoplasms 2Gliosarcoma 2Breast Carcinoma In Situ 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Tobacco Use Disorder 1Stomatitis 1Smoldering Multiple Myeloma 1Smoking 1Recurrence 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Precancerous Conditions 1

Interventions

Rituximab 4blinatumomab 3Whole-Body Irradiation 3Cyclophosphamide 3fludarabine phosphate 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Clofarabine 2treosulfan 1thymoglobulin 1sabatolimab 1pembrolizumab 1peginterferon alfa-2a 1obinutuzumab 1midostaurin 1ixazomib 1fludarabine 1eribulin 1daratumumab 1acalabrutinib 1Trastuzumab 1Tacrolimus 1Sodium Chloride 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm, Residual × Celecoxib × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡